These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33279940)

  • 1. Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing.
    Ahn JS; Kim T; Jung SH; Ahn SY; Jung SY; Song GY; Kim M; Yang DH; Lee JJ; Choi S; Lee JY; Park SK; Moon JH; Lee HY; Kim KH; Cai Y; Yi SY; Novitzky-Basso I; Zhang Z; Kim HJ; Kim DDH
    Bone Marrow Transplant; 2021 May; 56(5):1159-1170. PubMed ID: 33279940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
    Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
    Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.
    Lucero J; Alhumaid M; Novitzky-Basso I; Capo-Chichi JM; Stockley T; Gupta V; Bankar A; Chan S; Schuh AC; Minden M; Mattsson J; Kumar R; Sibai H; Tierens A; Kim DDH
    Ann Hematol; 2024 Apr; 103(4):1187-1196. PubMed ID: 38291275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
    Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.
    Rashidi A; Linden MA; DeFor TE; Warlick E; Bejanyan N; Yohe S; Weisdorf DJ; Ustun C
    Am J Hematol; 2017 Oct; 92(10):1032-1036. PubMed ID: 28646534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
    Appelbaum FR
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
    Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
    Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.
    Getta BM; Devlin SM; Levine RL; Arcila ME; Mohanty AS; Zehir A; Tallman MS; Giralt SA; Roshal M
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1064-1071. PubMed ID: 28315400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.
    Hourigan CS; Dillon LW; Gui G; Logan BR; Fei M; Ghannam J; Li Y; Licon A; Alyea EP; Bashey A; Deeg HJ; Devine SM; Fernandez HF; Giralt S; Hamadani M; Howard A; Maziarz RT; Porter DL; Scott BL; Warlick ED; Pasquini MC; Horwitz ME
    J Clin Oncol; 2020 Apr; 38(12):1273-1283. PubMed ID: 31860405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.
    Kim HJ; Kim Y; Kang D; Kim HS; Lee JM; Kim M; Cho BS
    Blood Cancer J; 2021 Jun; 11(6):109. PubMed ID: 34088902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT.
    Gilleece MH; Shimoni A; Labopin M; Robinson S; Beelen D; Socié G; Unal A; Ganser A; Vitek A; Sengeloev H; Yakoub-Agha I; Tholouli E; Polge E; Mohty M; Nagler A
    Blood Cancer J; 2021 May; 11(5):88. PubMed ID: 33980810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission.
    Jia X; Liao N; Yu S; Li H; Liu H; Zhang H; Xu J; Yao Y; He H; Yu G; Liu Q; Zhang Y; Shi P
    Cancer Med; 2024 Feb; 13(4):e7074. PubMed ID: 38457215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should patients with acute myeloid leukemia and measurable residual disease be transplanted in first complete remission?
    Buccisano F; Walter RB
    Curr Opin Hematol; 2017 Mar; 24(2):132-138. PubMed ID: 27930388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
    Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
    Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML.
    Morsink LM; Othus M; Bezerra ED; Wood BL; Fang M; Sandmaier BM; Mielcarek M; Schoch G; Storb R; Deeg HJ; Appelbaum FR; Walter RB
    Leukemia; 2020 Jun; 34(6):1577-1587. PubMed ID: 31974434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
    Wang J; Lu R; Wu Y; Jia J; Gong L; Liu X; Lu S; Wang Y; Yan C; Liu K; Zhang X; Xu L; Jiang Q; Zhao X; Shi H; Lai Y; Huang X; Ruan G; Jiang H
    Br J Haematol; 2020 Aug; 190(4):533-544. PubMed ID: 32090321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
    Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
    Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
    BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation.
    Wienecke CP; Heida B; Venturini L; Gabdoulline R; Krüger K; Teich K; Büttner K; Wichmann M; Puppe W; Neziri B; Reuter M; Dammann E; Stadler M; Ganser A; Hambach L; Thol F; Heuser M
    Blood; 2024 Jul; 144(3):296-307. PubMed ID: 38669617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.